drugset
Drugs / MVA.HIVconsv
last change Mar 2023 re-read 9 days ago

MVA.HIVconsv

also known as MVA

Vaccine

Developed for
HIV infectious disease · AIDS
Investigated by
University of Oxford · Medical Research Council · Fight AIDS and Infectious Diseases Foundation · GlaxoSmithKline · HIVACAT · Hospital Clinic of Barcelona
+18 more · IrsiCaixa · BCN Checkpoint · Brighton and Sussex University Hospitals NHS Trust · Central and North West London NHS Foundation Trust · Chelsea and Westminster NHS Foundation Trust · European and Developing Countries Clinical Trials Partnership (EDCTP) · Germans Trias i Pujol Hospital · Guy's and St Thomas' NHS Foundation Trust · Hospital de Sant Pau · Ichor Medical Systems Incorporated · Imperial College London · International AIDS Vaccine Initiative · Karolinska Institutet · ReiThera Srl · Royal Free Hospital NHS Foundation Trust · University College, London · University of Cambridge · University of Nairobi

Trials 8

today NCT02616874 · Ph 1 NCT02336074 · Ph 2 NCT02362217 · Ph 1 NCT02099994 · Ph 1/2 NCT02425241 · Ph 1/2 NCT01712425 · Ph 1 NCT01151319 · Ph 1 NCT01024842 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT02616874 Feb → Sep 2016 HIV infectious disease IrsiCaixa Completed No outcome recorded
Phase 1 NCT02362217 Oct 2014 → Aug 2016 HIV infectious disease, hepatitis C virus infection University of Oxford Completed No outcome recorded
Phase 1 NCT01712425 Oct 2012 → Oct 2015 HIV infectious disease IrsiCaixa Completed No outcome recorded
Phase 1 NCT01151319 Oct 2010 → Apr 2014 HIV infectious disease University of Oxford Completed No outcome recorded
Phase 1 NCT01024842 Dec 2009 → Nov 2013 — University of Oxford Terminated No outcome recorded Stop: Enrollment
Phase 1/22 trials
Phase 1/2 NCT02099994 Mar 2014 → Aug 2015 AIDS University of Oxford Completed No outcome recorded
Phase 1/2 NCT02425241 Oct 2013 → Feb 2016 HIV infectious disease University College, London Completed No outcome recorded
Phase 21 trial · 1 missed
Phase 2 NCT02336074 Nov 2015 → Nov 2017 HIV infectious disease Imperial College London Completed Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as MVA.HIVconsv “ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines” NCT01712425 ↗
7

NCT02616874 ↗

NCT02099994 ↗

NCT02362217 ↗

NCT02336074 ↗

NCT01024842 ↗

NCT02425241 ↗

NCT01151319 ↗
Known as MVA “ChAdV63.HIVconsv (ChAd) prime and MVA.HIVconsv (MVA) boost vaccines” NCT02336074 ↗
Modality Vaccine “the novel vaccine candidate, MVA.HIVconsv” NCT01024842 ↗
Route Intramuscular “Three intramuscular injections of MVA.HIVconsv alone” NCT01024842 ↗